Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 23 Oct 2025 | Laurent Muschel Director | Insert a brief description of the topic(s) discussed, e.g. Exchange of views on the reform of the Common Agriculture Policy, Discussion on the future Multiannual Financial Framework. | — |
| 23 Oct 2025 | Laurent Muschel Director | Insert a brief description of the topic(s) discussed, e.g. Exchange of views on the reform of the Common Agriculture Policy, Discussion on the future Multiannual Financial Framework. | SRC |
| 19 May 2025 | Florika Fink-Hooijer Director-General | Introductory meeting with GARDP | — |
| 19 May 2025 | Florika Fink-Hooijer Director-General | Introductory meeting with GARDP | SRC |
Mission & Goals
The Global Antibiotic R&D Partnership (GARDP) is a not-for-profit organization that works in partnership to develop new antibiotic treatments and expand access to them, specifically among the world’s most vulnerable populations. GARDP was created by WHO and DNDi in 2016 to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We develop new treatments to manage drug-resistant bacterial infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children. Our antibiotic development and access portfolio currently includes two approved treatments (cefiderocol and zoliflodacin - a novel oral treatment for treatment for gonorrhoea approved by the US FDA on 12 December 2025), and five investigational treatments (fosfomycin-amikacin, flomoxef-amikacin, fosfomycin-flomoxef, apramycin and BWC0977) for serious bacterial infections and sepsis in adults, children and newborns.
EU Legislative Interests
Antimicrobial Resistance (AMR), Antibiotic R&D and Access, Antimicrobials, One Health, Pandemic Preparedness, Global Health, Cross Border infectious disease threats, EU based antibiotic manufacturing, Poverty Related and Neglected Diseases, Access to Medicines, Economic models and Procurement Mechanisms for medical technologies of high public health value but with failing markets.
Communication Activities
Past and future events and meetings and (scientific and technical) publications around the areas of interest mentioned above.
Interests Represented
Does not represent commercial interests
Member Of
https://ghsacngs.org/ghsac-member-profiles/ https://www.ghtcoalition.org/our-members https://beam-alliance.eu/members/#members-associated https://eu-jamrai.eu/about/#stakeholders https://ohamr.eu/
Organisation Members
https://gardp.org/partners/